tiprankstipranks
Context Therapeutics price target raised to $10 from $4 at Maxim
PremiumThe FlyContext Therapeutics price target raised to $10 from $4 at Maxim
2M ago
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
PremiumPress Releases
Context Therapeutics Reports First Quarter 2024 Operating and Financial Results
2M ago
Context Therapeutics Secures Funding, Advances Clinical Trials
PremiumCompany Announcements
Context Therapeutics Secures Funding, Advances Clinical Trials
3M ago
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
PremiumPress ReleasesContext Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
4M ago
Context Therapeutics submits IND application for CTIM-76
PremiumThe Fly
Context Therapeutics submits IND application for CTIM-76
4M ago
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
PremiumPress Releases
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
4M ago
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
PremiumPress ReleasesContext Therapeutics Reports Third Quarter 2023 Operating and Financial Results
8M ago
Context Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
PremiumThe Fly
Context Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
9M ago
Context Therapeutics announces preclinical data on CTIM-76
PremiumThe Fly
Context Therapeutics announces preclinical data on CTIM-76
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100